Focusing on risk communication about medicines: Why now?

Drug Safety

Volumn 35, Issue 11, 2012, Pages 971-975

  Bahri, Priya ^a   Harrison Woolrych, Mira ^b  

^a EUROPEAN MEDICINES AGENCY   (United Kingdom)

^b UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

Risk communication.

Indexed keywords

DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; MEDICAL INFORMATION; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; RISK MANAGEMENT;

COMMUNICATION; DRUG MONITORING; DRUG TOXICITY; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; PHARMACOVIGILANCE; PHYSICIAN-PATIENT RELATIONS; RISK MANAGEMENT;

EID: 84867560852     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.2165/11640990-000000000-00000     Document Type: Review

References (32)

1. The future is now: current concepts in risk management [topical edition]. Drug Saf 2004; 27: 489-617
2. Edwards R, Hugman B. The challenge of effectively communicating risk-benefit information. Drug Saf 1997; 17: 216-27
3. Goldman SA. Communication of medical product risk: how effective is effective enough? Drug Saf 2004; 27: 519-34
4. Czarnecki A
5. Edwards IR, Lindquist M. Understanding and communicating key concepts in risk management: what do we mean by benefit and risk? Drug Saf 2009; 32: 449-52
6. Sanfélix-Gimeno G, Cervera-Casino P, Peiró S, et al. Effectiveness of safety warnings in atypical antipsychotic drugs: an interrupted time-series analysis in Spain. Drug Saf 2009; 32: 1075-87
7. Yong PL, Bigman C, Flynn DN, et al. Messages about black-box warnings: a comparative analysis of reports from the FDA and lay media in the US. Drug Saf 2009; 32: 1147-57
8. Mol PGM, Straus SMJM, Piening S, et al. A decade of safety-related regulatory action in the Netherlands: a retrospective analysis of direct healthcare professional communications from 1999-2009. Drug Saf 2010; 33: 463-74
9. Bahri P. Public pharmacovigilance communication: a process calling for evidence-based, objective-driven strategies. Drug Saf 2010; 33: 1065-79
10. Bahri P, Mol PGM, Théophile H, et al. Communication in drug safety: a report from an interactive debate held at the 10th Annual Meeting of the International Society of Pharmacovigilance (ISoP), 2010. Drug Saf 2011; 34: 881-2
11. Piening S, Haaijer-Ruskamp FM, de Vries JTN, et al. Impact of safety-related regulatory action on clinical review: a systematic review. Drug Saf 2012; 35: 373-85
12. Muehlberger N, Schneeweiss S, Hasford J. Adverse drug reaction monitoring: cost and benefit considerations. Part I: frequency of adverse drug reactions causing hospital admissions. Pharmacoepidemiol Drug Saf 1997; 6 Suppl. 3: S71-7
13. Goettler M, Schneeweiss S, Hasford J. Adverse drug reaction monitoring: cost and benefit considerations. Part II: cost and preventability of adverse drug reactions leading to hospital admission. Pharmacoepidemiol Drug Saf 1997; 6 Suppl. 3: S79-90
14. Pouyanne P, Haramburu F, Imbs JL, et al. Admissions to hospital caused by adverse drug reactions: cross-sectional incidence study. BMJ 2000; 320: 1036
15. Phillips J, Beam S, Brinker A, et al. Retrospective analysis of mortalities associated with medication errors. Am J Health System Pharm 2001; 58: 1835-41
16. Beijer HJM, Blaey de CJ. Hospitalisations caused by adverse reactions (ADR): a meta-analysis of observational studies. Pharm World Sci 2002; 24: 46-54
17. Institute of Medicine of the National Academies (IOM). Preventing medication errors. Washington, DC: National Academies Press, 2006
18. Howard RL, Avery AJ, Slavenburg S, et al. Which drugs cause preventable admissions to hospital? A systematic review. Br J Clin Pharmacol 2006; 63: 136-47
19. Council of Europe Expert Group on Safe Medication Practices. Creation of a better medication safety culture in Europe: building up safe medication practices. Strasbourg: Council of Europe, 2007
20. Leendertse AJ, Egberts ACG, Stoker LJ, et al., for the HARM study group. Frequency of and risk factors for preventable medication-related hospital admissions in the Netherlands. Arch Intern Med 2008; 168: 1890-6
21. Hakkarainen KM, Hedna K, Petzold M, et al. Percentage of patients with preventable adverse drug reactions and preventability of adverse drug reactions: a meta-analysis. PLoS One 2012; 7: e33236, 1-9
22. International Alliance of Patients' Organizations. IAPO policy statement on patient information. London: International Alliance of Patients' Organizations, 2009
23. Cox AR, Butt TF. Adverse drug reactions: when the risk becomes a reality for patients. Drug Saf 2012; 35 (11): 977-81
24. Dodoo A, Hugman B. Risk perception and communication in sub-Saharan Africa. Drug Saf 2012; 35 (11): 1041-52
25. Hartigan-Go K. Challenges of drug risk communications in the Philippines. Drug Saf 2012; 35 (11): 995-1004
26. Piening S, Haaijer-Ruskamp FM, de Graeff PA, et al. Healthcare professionals' self-reported experiences and preferences related to direct healthcare professional communications: a survey conducted in the Netherlands. Drug Saf 2012; 35 (11): 1061-72
27. Edwards B, Chakraborty S
28. Fischhoff B. Good decision making requires good communication. Drug Saf 2012; 35 (11): 983-93
29. Larson H, Brocard Paterson P, Erondu N. The globalization of risk and risk perception: why we need a new model of risk communication for vaccines. Drug Saf 2012; 35 (11): 1053-9
30. Hugman B. Protecting the people? Risk communication and the chequered history and performance of bureaucracy. Drug Saf 2012; 35 (11): 1005-25
31. Uppsala Monitoring Centre. Effective communication in pharmacovigilance: the Erice report (report on the International Conference on Developing Effective Communications in Pharmacovigilance held in Erice, 24-27 September 1997, organised by the UMC, the World Health Organization, the University of Verona, the International School of Pharmacology, the Ettore Majorana Centre for Scientific Culture and supported by EQUUS Communications). Uppsala: Uppsala Monitoring Centre, 1997
32. Erice statement 2009: communication, medicines and patient safety. Br J Clin Pharmacol 2010; 69: 207-8